
Cingulate (CING) Stock Forecast & Price Target
Cingulate (CING) Analyst Ratings
Bulls say
Cingulate is a clinical-stage biopharmaceutical company with a positive outlook due to its large market potential in the treatment of ADHD and anxiety. The company's recent CEO transition may pose risks, but with a strong focus on product development and promising data for their proprietary drugs utilizing the Precision Timed Release (PTR) technology, Cingulate's current valuation is attractive and presents significant upside potential for investors in the biotech industry.
Bears say
Cingulate is a clinical stage biopharmaceutical company with a negative outlook due to its focus on ADHD and anxiety, limited cash on hand until mid-2027, and potential approval and commercialization timeline of mid or late-2026. This could lead to financial difficulties in the interim, as evidenced by the recent Q3 report showing a net loss of $7.3 million and lack of revenue due to its in-development status.
This aggregate rating is based on analysts' research of Cingulate and is not a guaranteed prediction by Public.com or investment advice.
Cingulate (CING) Analyst Forecast & Price Prediction
Start investing in Cingulate (CING)
Order type
Buy in
Order amount
Est. shares
0 shares